Form 4: Cara Therapeutics Director Lisa von Moltke Reports Stock and Option Awards

Director Lisa von Moltke reported the acquisition of stock and option awards from Cara Therapeutics, Inc.

Summary

• Lisa von Moltke, a director of Cara Therapeutics, Inc., reported transactions involving the company's securities.
• On June 4, 2024, Ms. von Moltke acquired 150,647 shares of common stock through restricted stock units (RSUs) and disposed of 183,009 shares.
• She also acquired options to purchase 195,000 shares of common stock at an exercise price of $0.664.
• The RSUs and options vest on the earlier of June 4, 2025, or immediately prior to the Issuer's next annual meeting of stockholders following the grant date, contingent upon continued service as a director.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard compensation practices, aligning director interests with shareholders through equity.

Positives

• The grant of RSUs and options to a director aligns their interests with those of the shareholders.
• The vesting conditions incentivize continued service and commitment to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the granted securities.

Industry Context

This filing is a routine disclosure of equity-based compensation for a company director, common in the pharmaceutical industry to align management and shareholder interests.

Comparison to Industry Standards

• Equity compensation for board members is a standard practice across the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Biogen also grant stock options and restricted stock units to their directors as part of their compensation packages.
• The vesting schedules and amounts are generally comparable, varying based on company size, performance, and individual contributions.

Stakeholder Impact

• The equity grants align the director's interests with those of shareholders, potentially driving decisions that increase shareholder value.
• The vesting schedule incentivizes the director to remain engaged and contribute to the company's success.

Key Dates